Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer
Fraser R Millar1, Adam Pennycuick2, Morwenna Muir1
1Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XR, UK.
Abstract:
Targeting early-stage lung cancer is vital to improve survival. However, the mechanisms and components of the early tumor suppressor response in lung cancer are not well understood. In this report, we study the role of Toll-like receptor 2 (TLR2), a regulator of oncogene-induced senescence, which is a key tumor suppressor response in premalignancy. Using human lung cancer samples and genetically engineered mouse models, we show that TLR2 is active early in lung tumorigenesis, where it correlates with improved survival and clinical regression. Mechanistically, TLR2 impairs early lung cancer progression via activation of cell intrinsic cell cycle arrest pathways and the proinflammatory senescence-associated secretory phenotype (SASP). The SASP regulates non-cell autonomous anti-tumor responses, such as immune surveillance of premalignant cells, and we observe impaired myeloid cell recruitment to lung tumors after Tlr2 loss. Last, we show that administration of a TLR2 agonist reduces lung tumor growth, highlighting TLR2 as a possible therapeutic target.
Insights
Toll-like receptor 2 (TLR2) acts as a tumor suppressor in early lung cancer by inducing senescence and immune responses. Activating TLR2 may be a promising therapeutic strategy for lung cancer patients.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Early-stage lung cancer detection and treatment are crucial for improving patient survival rates.
- The precise mechanisms of early tumor suppression in lung cancer remain incompletely understood.
- Oncogene-induced senescence is a critical tumor suppressor mechanism during premalignant stages.
Purpose of the Study:
- To investigate the role of Toll-like receptor 2 (TLR2) in early lung cancer suppression.
- To elucidate the molecular pathways through which TLR2 exerts its tumor-suppressive effects.
- To evaluate the therapeutic potential of TLR2 agonists in lung cancer treatment.
Main Methods:
- Analysis of human lung cancer samples.
- Utilized genetically engineered mouse models of lung cancer.
- Investigated the impact of TLR2 activation on cell cycle arrest and senescence-associated secretory phenotype (SASP).
- Assessed immune cell recruitment to tumors following Tlr2 manipulation.
- Evaluated the efficacy of a TLR2 agonist in reducing lung tumor growth.
Main Results:
- TLR2 is actively involved in early lung tumorigenesis and correlates with improved survival and tumor regression.
- TLR2 suppresses early lung cancer progression by activating cell-intrinsic cell cycle arrest and the SASP.
- Loss of TLR2 function leads to impaired myeloid cell recruitment and reduced anti-tumor immune surveillance.
- Administration of a TLR2 agonist effectively reduced lung tumor growth in preclinical models.
Conclusions:
- TLR2 functions as a key early tumor suppressor in lung cancer through senescence induction and modulation of the tumor microenvironment.
- TLR2-mediated SASP promotes non-cell autonomous anti-tumor immunity, including immune surveillance.
- Targeting TLR2 with agonists represents a potential therapeutic strategy for early-stage lung cancer.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:39lncRNA - Long Non-coding RNAs
02:23Abnormal Proliferation
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:16TGF - β Signaling Pathway